Discover 2,576 paid clinical trials in Illinois. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Illinois offers various clinical research options, including those for healthy volunteers interested in paid studies, as well as for individuals with specific health conditions. Leading research centers in Chicago, Plainfield, and Springfield are actively seeking participants, providing access to innovative treatments and personalized care.
Filter
1
Filter results
Results: 2,576
TVMR With the INNOVALVE System Trial - Early Feasibility Study
for
Mitral Valve Regurgitation (Degenerative or Functional)
Location: Manhasset NY, New York NY, Morristown NJ,
Sponsor: Edwards Lifesciences
Sex: All
Age: 18+
Code: NCT04919980
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
for
Urothelial Carcinoma
Location: Worcester MA, Commack NY, Uniondale NY, Harrison NY,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All
Age: 18+
Code: NCT04879329
Phase2, Recruiting
MRI Screening in Men at High Risk of Developing Prostate Cancer
for
Prostate Cancer Screening
Location: Chicago IL, Glenview IL
Sponsor: University of Chicago
Sex: Male
Age: 18+
Code: NCT05608694
Recruiting
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
for
Brain Metastases
Location: Halifax, Boston MA, Quebec, Egg Harbor NJ, Montreal,
Sponsor: Canadian Cancer Trials Group
Sex: All
Age: 18+
Code: NCT03550391
Phase3, Recruiting
Once Weekly Infant Corticosteroid Trial for DMD
for
Duchenne Muscular Dystrophy
Location: Columbus OH, Cincinnati OH, Chicago IL, Dallas TX
Sponsor: Anne M. Connolly
Sex: Male
Age: 0 - 2
Code: NCT05412394
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
for
NonSegmental Vitiligo
Location: St. John's, Halifax, Boston MA, Quebec, Woodbury NY,
Sponsor: Incyte Corporation
Sex: All
Age: 2 - 11
Code: NCT06548360
Phase3, Recruiting
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
for
B-cell Non-Hodgkin Lymphoma (B-NHL)
Location: Boston MA, New Brunswick NJ, Chicago IL, Austin TX
Sponsor: Cellectis S.A.
Sex: All
Age: 18 - 70+
Code: NCT05607420
Phase1, Phase2, Recruiting
His-Bundle Corrective Pacing in Heart Failure
for
Right Bundle-Branch Block, Heart Failure, His-bundle Pacing,
Location: New York NY, Ridgewood NJ, Burlington VT,
Sponsor: University of Rochester
Sex: All
Age: 18+
Code: NCT05265520
Recruiting
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
for
Sickle Cell Disease
Location: The Bronx NY, Staten Island NY, Baltimore MD,
Sponsor: Sanofi
Sex: All
Age: 10 - 65
Code: NCT06975865
Phase3, Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
for
COPD (Chronic Obstructive Pulmonary Disease)
Location: Sydney, Boston MA, Quebec, Massapequa NY, The Bronx NY,
Sponsor: AstraZeneca
Sex: All
Age: 40 - 70+
Code: NCT06283966
Phase3, Recruiting
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
Location: Brewer ME, Gloucester MA, South Weymouth MA, Beverly MA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT06661720
Phase3, Recruiting
Rare and Atypical Diabetes Network
for
Diabetes Mellitus, Diabetes Mellitus Progression,
Location: Boston MA, Brooklyn NY, New York NY, Baltimore MD,
Sponsor: University of South Florida
Sex: All
Age: 0+
Code: NCT05544266
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
for
Metastatic Castration-resistant Prostate Cancer (mCRPC),
Location: New Haven CT, Quebec, New Brunswick NJ, Montreal,